摘要
75例高脂血症患者按血脂水平以2∶1配对随机分组,50例服氧甲吡嗪,25例服非诺贝特作为对照。12周后两组血清总胆固醇与甘油三酯下降,高密度脂蛋白胆固醇升高均较治疗前有明显差异。氧甲吡嗪降甘油三酯作用不如对照组,但副作用较少。
Olbetam (5-methylpyrazine carboxylic acid 4-oxide), an analogue of nicotinic acid, is a new blood lipid modulator. A comparative study on the effects of olbetam (750mg/day) in 55 patients and fenofibrate (300mg/day) in 25 patients with hyperlipidemia was carried out. At the end of a 12 week trial, serum total cholesterol (TC) decreased by 9.2% (P<0.001) with olbetam and 16.2% (P<0.001) with fenofibrate,serum triglyceride (TC) decreased by 27.5% (P<0.001) and 52.8% (P<0.001) respectively. It also caused a statistically significant increase in high density lipoprotein cholesteral (HDL-C) by 19.2% and 30.7% respectively. No significant differences between both groups in TC, TG and HDL-C were observed. The side effect of oibetam was less than that of fenofibrate. It is suggested that olbetam is an effective and tolerable lipid modulator.
出处
《中国循环杂志》
CSCD
1992年第1期27-29,共3页
Chinese Circulation Journal
关键词
氧甲吡嗪
非诺贝特
高血脂病
Olbetam
Fenofibrate
Cholesterol
Triglyceride
High density lipoprotein cholesteral
